The Burden of Anxiousness- and Distress-Related Behaviors in Prader-Willi Syndrome

Elizabeth E. Roof¹, Deborah L. Hoffman², Alana Salvucci³, Ratna Revankar³, Shuyan Zhang², Yonghua Chen², Sheri E. Fehnel⁴

¹Vanderbilt University, Nashville, TN, USA; ²Acadia Pharmaceuticals Inc., San Diego, CA, USA; ³Acadia Pharmaceuticals Inc., Princeton, NJ, USA; ⁴RTI Health Solutions, Durham, NC, USA



30

-BACKGROUND

The Prader-Willi Anxiousness and Distress Behaviors

levels of anxiousness and psychological distress

not included in the total score

carbetocin (NCT03649477)⁶

Table 1. The PADQ: Items and Scoring System

1: Ask for excessive details about schedule

3: Repeat the same or similar question

7: Concern about his/her possessions

4: Pace/move in agitated way

5: Engage in nervous habits

2: Confirm/review information already known

6: Concern when separating from caregiver

8: Engage in self-soothing/comforting activity

9: Worried about possible changes in plans

10: Upset when change happened to plans

11: Hard time calming down when upset

12: Emotional outburst something done

14: Ask about upcoming meals/snacks

15: Anxious or distressed in some way

PADQ, Prader-Willi Anxiousness and Distress Behaviors Questionnaire

with PWS for whom they provided care

qualitative interviews⁵

• The PADQ is a validated 15-item caregiver-reported instrument designed

behaviors that are common among individuals with PWS (**Table 1**)

to capture the observable signs of anxiousness- and distress-related

- The PADQ total score (range, 0–56) is computed based on responses

("never") to 4 ("always/almost always"); higher scores indicate greater

- The 15th item is an overall summary of caregivers' observations and is

The PADQ was developed in collaboration between clinical experts and

caregivers of individuals with PWS, who participated in iterative sets of

Caregivers consistently endorsed the items on the PADQ and indicated

that these items comprehensively captured the behaviors associated

confirmed using data from the phase 3 CARE-PWS trial of intranasal

0 = Never

1 = Rarely

3 = Often

2 = Sometimes

4 = Always or almost always

Total score ranges from 0–56

(higher scores indicate greater levels

of anxiety and psychological distress)

Score during past 7 days

with anxiousness and distress that were observed in the individuals

The psychometric properties of the PADQ were subsequently

to the first 14 items of the measure, with each item scored from 0

Questionnaire

- Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder characterized by early childhood—onset hyperphagia and a behavioral phenotype that
 includes high levels of anxiousness- and distress-related behaviors that can be food- or non—food-related¹
- Anxiousness- and distress-related behaviors frequently lead to conflict and temper tantrums that negatively impact the daily functioning and quality of life of individuals with PWS and their families²
- Caregivers have identified the treatment of hyperphagia and anxiety as among the most significant unmet needs in PWS³
- Many of the unique signs of anxiousness- and distress-related behaviors commonly observed in PWS (eg, repetitive questioning) are not among the criteria used to define anxiety disorders in the Diagnostic and Statistical Manual of Mental Disorders 5th edition,⁴ and the key triggers for anxiousness and distress common in PWS (eg, food, schedules, routines, and unexpected change) differ from anxiety-provoking situations of concern to those with anxiety disorders⁵
- Furthermore, assessments of anxiety used in the general population are typically self-reported, which is not appropriate for those with PWS given the
 intellectual disability and deficits in social cognition, and most measures include behaviors that are not relevant to PWS and/or do not include aspects of
 anxiousness that are pertinent in PWS⁵
- The Prader-Willi Anxiousness and Distress Behaviors Questionnaire (PADQ) is a PWS-specific, caregiver-reported assessment that was developed to address these limitations

RESULTS

Frequency Distribution of Caregiver Responses Individual PADQ Behaviors

- Almost all (89%) caregivers reported that individuals with PWS were often (52%) or always/almost always (37%) anxious or distressed in some way during the past 7 days based on their response to item 15 of the PADQ (Figure 1)
- Behaviors that were reported as occurring always/almost always by the majority of caregivers included repeatedly asking about meals and snacks (77%), confirming information already known (72%), and food anxiety (71%) (**Figure 1**)
- Notably, all caregivers reported that these behaviors were observed at least sometimes, with none indicating that they never or rarely occurred
- Five additional behaviors that were mostly reported as occurring always/almost always were asking excessive details about schedules (71%), repetitive questioning (67%), worry about possible schedule changes (56%), nervous habits like skin picking and finger biting (46%), and upset when schedules/routines changed (35%) (**Figure 1**)
- Less than 4% of caregivers reported that each of these behaviors were never observed
- Other behaviors described as occurring often to always/almost always in more than half the total sample included engaging in self-soothing/comforting, emotional outbursts, concern about possessions, and difficulty calming down when upset (**Figure 1**)
- Only a small minority (approximately 4% or less) reported that these behaviors were never observed
- Behaviors addressed in the PADQ that were reported to occur least frequently were concern when separating from caregivers and pacing/moving in an agitated manner, which were never observed by 14% and 8% of caregivers, respectively (**Figure 1**)
- However, more than one-third of caregivers still reported that these behaviors were observed often to always/almost always

Total PADQ Score

Total PADQ scores at baseline were in the upper 50th percentile
of the scoring range (ie, total score >28) for all but 1 study
participant (118 of 119), indicating that anxiousness- and
distress-related behaviors were not only common, but also
frequently observed across the entire study sample at baseline
(Figure 2)


encompassed within the PADQ during the past 7 days at baseline (and follow-up time points)

- METHODS

STUDY OBJECTIVE

PADQ data from the CARE-PWS study

daily) in 119 participants with PWS aged 7–18 years



To evaluate the caregiver-reported burden of anxiousness- and distress-related behaviors in PWS using baseline


• The phase 3, placebo-controlled CARE-PWS trial investigated the efficacy and safety of intranasal carbetocin (3.2 mg or 9.6 mg, 3 times

• Caregivers were asked to rate the frequency with which they observed the study participants engaging in each of the behaviors

PADQ behaviors that were most frequently reported as always/almost always are grouped to the left and behaviors that were reported as never occurring are aligned in descending order from right to left PADQ, Prader-Willi Anxiousness and Distress Behaviors Questionnaire

Descriptive statistics were computed to summarize the data provided by caregivers at baseline

Figure 2. Frequency Distribution of Total PADQ Score Reported by Caregivers at Baseline



CONCLUSIONS

13: Anxious about food

1-14: Total Score

- PADQ behaviors and total scores at baseline characterize the high burden of anxiousness in PWS and highlight the important role the PADQ can play in assessing meaningful change due to treatment
- These findings provide additional context to interpret previously published PADQ results from the CARE-PWS trial, showing patients treated with the 3.2-mg dose of intranasal carbetocin (but not the 9.6-mg dose) achieved significant improvements in anxiousness vs placebo, which were sustained in the 56-week follow-up

REFERENCES

- 1. Cassidy SB, et al. *Genet Med*. 2012;14(1):10–26.
- 2. Schwartz L, et al. *J Neurodev Disord*. 2021;13(1):25.
- 3. Tsai J-H, et al. *J Med Economics*. 2018;21(12):1230–1237.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Text Revision (DSM-5-TR). Arlington, VA: American Psychiatric Publishing; 2022.
- 5. Cotter SP, et al. *Value Health*. 2023;26(2):243–250.
- 6. Roof E, et al. *J Clin Endocrinol Metab.* 2023;108(7):1696–1708.

ACKNOWLEDGMENTS

Acadia Pharmaceuticals Inc. thanks the CARE-PWS investigators and study participants. Medical writing support was provided by Stuart Murray, MSc, of Envision Spark, an Envision Medical Communications agency, a part of Envision Pharma Group and funded by Acadia Pharmaceuticals Inc. Presentation support was provided by Karissa Burroughs, PharmD, of Acadia Pharmaceuticals Inc.

DISCLOSURES

EER has received funding from Acadia Pharmaceuticals Inc. **DLH**, **AS**, **RR**, **SZ**, and **YC** are employees of and stakeholders in Acadia Pharmaceuticals Inc. **SEF** was an employee of RTI Health Solutions at the time this study was conducted.

